drugset / Trial / NCT07365462
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
Timeline
- Start
- 2026-02-06
- Primary completion
- 2027-02
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NBI-1065890 | Unknown | — | Oral |